@article{568dc5237fa747e3b38b0489cc2dfb03,
title = "Telemedicine and Deep brain stimulation - Current practices and recommendations",
abstract = "The use of telemedicine in the management of chronic neurological conditions including movement disorders has expanded over time. In addition to enabling remote access to specialized care, telemedicine has also been shown to reduce caregiver burden and to improve patient satisfaction. With the COVID-19 pandemic, implementation of telehealth for patients with movement disorders, particularly those with more severe mobility issues, has increased rapidly. Although telemedicine care has been shown to be effective for patients with various movement disorders, its utilization for patients with device aided therapies such as deep brain stimulation (DBS) is limited due to challenges related to adjusting these devices remotely and to the lack of consensus recommendations for using telemedicine in this patient population. Thus, guidelines for telemedicine and DBS will assist clinicians on the appropriate implementation of telemedicine to provide care to DBS patients. Optimizing the use of telemedicine for DBS will expand this type of therapy to remote locations with limited access to programming expertise, and also reduce the need for patient travel. Telemedicine is particularly important during the ongoing pandemic due to infection risk and limited access to clinic visits. In this article we review the currently available and emerging strategies for telemedicine and remote care for DBS. We then outline common principles and recommendations for telemedicine care in patients with DBS, review patient selection and best practices. Finally, we briefly discuss the current state of reimbursement for DBS telemedicine visits.",
keywords = "DBS programming, Deep brain stimulation, Remote care, Telemedicine, Teleneurology",
author = "Sharma, {Vibhash D.} and Delaram Safarpour and Mehta, {Shyamal H.} and Nora Vanegas-Arroyave and Daniel Weiss and Cooney, {Jeffrey W.} and Zoltan Mari and Alfonso Fasano",
note = "Funding Information: ZM has received (institutional) grant support from the National Institution of Health, the Michael J Fox Foundation, the Parkinson's Foundation , AbbVie , Eli Lilly , Biogen , Cerevel, and Amneal. ZM also received consulting honoraria from GB Sciences, Biogen, Sanofi-Genzyme, Global Kinetics Corporation, Amneal, Abvie, Kyowa-Kirin, US World Meds/Supernus, and Acadia. ZM currently serves as the Chair of the Telemedicine Study Group for the Movement Disorder Society, Co-Chair of the Motor Working Group of the Parkinson Study Group, and Associate Editor of the Parkinsonism and Related Disorders Journal. ZM is also co-founder and Chief Medical Officer of Neuraly Inc. and Z NeuroSciences, Inc. Funding Information: DW has received honoraria for consultancies or as speaker fee from Abbvie, Abbott, Boston Scientific, Medtronic, STADA. He is in advisory boards for Abbott, STADA. He has received research grants from Boston Scientific, Abbott, Medtronic, Michael J FoxFoundation, and the German Research Council. Is in the Editorial Board of Frontiers Neurology.JWC has received fellowship funding support from Abbott, Allergan, Boston Scientific, and Medtronic, and has received honoraria from Abbott, AbbVie, Acadia, Accorda, Amneal, Medtronic, and the Parkinson'sFoundation. JC has also received institutional grant support from the National Institutes of Health and the Michael J. Fox Foundation.ZM has received (institutional) grant support from the National Institution of Health, the Michael J FoxFoundation, the Parkinson'sFoundation, AbbVie, Eli Lilly, Biogen, Cerevel, and Amneal. ZM also received consulting honoraria from GB Sciences, Biogen, Sanofi-Genzyme, Global Kinetics Corporation, Amneal, Abvie, Kyowa-Kirin, US World Meds/Supernus, and Acadia. ZM currently serves as the Chair of the Telemedicine Study Group for the Movement Disorder Society, Co-Chair of the Motor Working Group of the Parkinson Study Group, and Associate Editor of the Parkinsonism and Related Disorders Journal. ZM is also co-founder and Chief Medical Officer of Neuraly Inc. and Z NeuroSciences, Inc.AF has received honoraria for consultancies or as speaker fee from Abbvie, Abbott, Boston Scientific, Brainlab, Inbtrain, Ipsen, Medtronic, Merz, Sunovion, Paladin, and UCB. He sits in advisory boards for Abbvie, Boston Scientific, Ceregate, Inbrain, and Ipsen, and has received research grants from Abbvie, Boston Scientific, University of Toronto, Michael J FoxFoundation, and Medtronic. Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = aug,
doi = "10.1016/j.parkreldis.2021.07.001",
language = "English (US)",
volume = "89",
pages = "199--205",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
}